Mountain Valley MD Holdings Inc. announce that it has filed a POROUS ALUMINUM NANO-STRUCTURED ADJUVANT ("PANA") patent to protect the Company's advanced work on vaccine dose sparing. The PANA patent includes a novel adjuvant that was invented with the objective to be fully compatible with current vaccine manufacturing methods, a critical element of the Company's strategy to introduce technologies that offer simplicity for partner adoption and enable cost effective solutions that can be quickly brought to market.